Zacks Investment Research
25 Jun 2026, 14:55 UTC · 14w ago
Verdict
Headline leans bullish. We score NTRA +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
More positive than 99% of ticker scores this week
Search tags
What the story claims
3 claims · scored −1 bearish … +1 bullish
Natera's Signatera test received PMDA approval in Japan for use in colorectal cancer patients in the adjuvant setting.
More positive than 93% of claims this week
Natera plans to commercially launch Signatera in Japan by the end of 2026, pending pricing and reimbursement decisions.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 78% of claims this week
Natera intends to submit muscle-invasive bladder cancer for regulatory approval in Japan as its next expansion step.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Received PMDA approval in Japan for Signatera, representing a major milestone in international expansion and driving a 10.7% share price increase.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
13h ago
+57.8%
Price agrees with the score
$410.35 vs $259.97 close before publication (Jun 24) · not market-adjusted
NTRA chart →
